Skip to main content

Advertisement

SpringerLink
Log in

Early systemic sclerosis—opportunities for treatment

  • Review Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Systemic sclerosis (SSc) is characterized by microvasculopathy (Raynaud’s phenomenon and fibrointimal proliferation), presence of autoantibodies and collagen deposition in skin (scleroderma) and internal organs. Microvasculopathy, detected by nailfold capillaroscopy, and disease-specific autoantibodies (anti-topoisomerase I, anti-centromere, anti-RNA polymerase III antibodies) usually appear earlier, even years before scleroderma. At that stage of the disease, immune activation with T cells and B cells promote fibrosis. Diagnosis of SSc has been relied on scleroderma, and by this time, internal organs may have developed fibrosis, a lethal feature with no available treatment. The new EULAR/ACR 2013 criteria for the classification of SSc will help identify SSc patients before fibrosis of internal organs. The early diagnosis of SSc, before the development of fibrosis in internal organs, will allow the introduction of immunosuppressive medications in these patients in a controlled setting (randomized trials). It is anticipated that this approach will change the hitherto grim prognosis of SSc for the better.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Meier FM, Frommer KW, Dinser R, Walker UA, Czirjak L, Denton CP et al (2012) Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 71:1355–1360

    Article  PubMed  Google Scholar 

  2. Mouthon L, Mestre-Stanislas C, Berezne A, Rannou F, Guilpain P, Revel M et al (2010) Impact of digital ulcers on disability and health-related quality of life in systemic sclerosis. Ann Rheum Dis 69:214–217

    Article  CAS  PubMed  Google Scholar 

  3. Savarino E, Mei F, Parodi A, Ghio M, Furnari M, Gentile A et al (2013) Gastrointestinal motility disorder assessment in systemic sclerosis. Rheumatology (Oxford) 52:1095–1100

    Article  CAS  Google Scholar 

  4. Steen VD, Medsger TA Jr (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43:2437–2444

    Article  CAS  PubMed  Google Scholar 

  5. Campo A, Mathai SC, Le Pavec J, Zaiman AL, Hummers LK, Boyce D et al (2010) Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 182:252–260

    Article  PubMed  PubMed Central  Google Scholar 

  6. Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE et al (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69:1809–1815

    Article  PubMed  Google Scholar 

  7. Guillevin L, Berezne A, Seror R, Teixeira L, Pourrat J, Mahr A et al (2012) Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. Rheumatology (Oxford) 51:460–467

    Article  CAS  Google Scholar 

  8. Nikpour M, Baron M (2014) Mortality in systemic sclerosis: lessons learned from population-based and observational cohort studies. Curr Opin Rheumatol 26:131–137

    Article  PubMed  Google Scholar 

  9. Goldin J, Elashoff R, Kim HJ, Yan X, Lynch D, Strollo D et al (2009) Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. Chest 136:1333–1340

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Broad K, Pope JE (2010) The efficacy of treatment for systemic sclerosis interstitial lung disease: results from a meta-analysis. Med Sci Monit 16:RA187–RA190

    PubMed  Google Scholar 

  11. Gerbino AJ, Goss CH, Molitor JA (2008) Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 133:455–460

    Article  CAS  PubMed  Google Scholar 

  12. Koutroumpas A, Ziogas A, Alexiou I, Barouta G, Sakkas LI (2010) Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol 29:1167–1168

    Article  PubMed  Google Scholar 

  13. Le EN, Wigley FM, Shah AA, Boin F, Hummers LK (2011) Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis 70:1104–1107

    Article  CAS  PubMed  Google Scholar 

  14. Mendoza FA, Nagle SJ, Lee JB, Jimenez SA (2012) A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol 39:1241–1247

    Article  CAS  PubMed  Google Scholar 

  15. Launay D, Sitbon O, Le Pavec J, Savale L, Tcherakian C, Yaici A et al (2010) Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology (Oxford) 49:490–500

    Article  CAS  Google Scholar 

  16. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C et al (2010) Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 49:271–280

    Article  CAS  Google Scholar 

  17. Bosello S, De Santis M, Lama G, Spano C, Angelucci C, Tolusso B et al (2010) B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 12:R54

    Article  PubMed  PubMed Central  Google Scholar 

  18. Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y et al (2014) Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-204522

    PubMed Central  Google Scholar 

  19. (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23:581–590

  20. Ho YY, Lagares D, Tager AM, Kapoor M (2014) Fibrosis—a lethal component of systemic sclerosis. Nat Rev Rheumatol 10:390–402

    Article  CAS  PubMed  Google Scholar 

  21. Sakkas LI, Chikanza IC, Platsoucas CD (2006) Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheumatol 2:679–685

    Article  CAS  PubMed  Google Scholar 

  22. Gerber EE, Gallo EM, Fontana SC, Davis EC, Wigley FM, Huso DL et al (2013) Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma. Nature 503:126–130

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G et al (2008) Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 58:3902–3912

    Article  PubMed  Google Scholar 

  24. Freemont AJ, Hoyland J, Fielding P, Hodson N, Jayson MI (1992) Studies of the microvascular endothelium in uninvolved skin of patients with systemic sclerosis: direct evidence for a generalized microangiopathy. Br J Dermatol 126:561–568

    Article  CAS  PubMed  Google Scholar 

  25. Prescott RJ, Freemont AJ, Jones CJ, Hoyland J, Fielding P (1992) Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 166:255–263

    Article  CAS  PubMed  Google Scholar 

  26. Rodnan GP, Lipinski E, Luksick J (1979) Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 22:130–140

    Article  CAS  PubMed  Google Scholar 

  27. Sakkas LI, Xu B, Artlett CM, Lu S, Jimenez SA, Platsoucas CD (2002) Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 168:3649–3659

    Article  CAS  PubMed  Google Scholar 

  28. O’Reilly S, Hugle T, van Laar JM (2012) T cells in systemic sclerosis: a reappraisal. Rheumatology (Oxford) 51:1540–1549

    Article  Google Scholar 

  29. Brembilla NC, Montanari E, Truchetet ME, Raschi E, Meroni P, Chizzolini C (2013) Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts. Arthritis Res Ther 15:R151

    Article  PubMed  PubMed Central  Google Scholar 

  30. Henault J, Robitaille G, Senecal JL, Raymond Y (2006) DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. Arthritis Rheum 54:963–973

    Article  CAS  PubMed  Google Scholar 

  31. Pierce EM, Carpenter K, Jakubzick C, Kunkel SL, Flaherty KR, Martinez FJ et al (2007) Therapeutic targeting of CC ligand 21 or CC chemokine receptor 7 abrogates pulmonary fibrosis induced by the adoptive transfer of human pulmonary fibroblasts to immunodeficient mice. Am J Pathol 170:1152–1164

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Nishijima C, Hayakawa I, Matsushita T, Komura K, Hasegawa M, Takehara K et al (2004) Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clin Exp Immunol 138:357–363

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Odaka M, Hasegawa M, Hamaguchi Y, Ishiura N, Kumada S, Matsushita T et al (2010) Autoantibody-mediated regulation of B cell responses by functional anti-CD22 autoantibodies in patients with systemic sclerosis. Clin Exp Immunol 159:176–184

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M et al (2006) Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354:2667–2676

    Article  CAS  PubMed  Google Scholar 

  35. Classen JF, Henrohn D, Rorsman F, Lennartsson J, Lauwerys BR, Wikstrom G et al (2009) Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis. Arthritis Rheum 60:1137–1144

    Article  CAS  PubMed  Google Scholar 

  36. Loizos N, Lariccia L, Weiner J, Griffith H, Boin F, Hummers L et al (2009) Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera. Arthritis Rheum 60:1145–1151

    Article  CAS  PubMed  Google Scholar 

  37. LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28:1573–1576

    CAS  PubMed  Google Scholar 

  38. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 65:2737–2747

    Article  PubMed  PubMed Central  Google Scholar 

  39. Johnson SR, Fransen J, Khanna D, Baron M, van den Hoogen F, Medsger TA Jr et al (2012) Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res 64:358–367

    Article  Google Scholar 

  40. Pavlov-Dolijanovic S, Damjanov NS, Stojanovic RM, Vujasinovic Stupar NZ, Stanisavljevic DM (2012) Scleroderma pattern of nailfold capillary changes as predictive value for the development of a connective tissue disease: a follow-up study of 3,029 patients with primary Raynaud’s phenomenon. Rheumatol Int 32:3039–3045

    Article  PubMed  Google Scholar 

  41. Rodnan GP, Myerowitz RL, Justh GO (1980) Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. Medicine (Baltimore) 59:393–408

    Article  CAS  Google Scholar 

  42. Bruni C, Guiducci S, Bellando-Randone S, Lepri G, Braschi F, Fiori G et al (2015) Digital ulcers as a sentinel sign for early internal organ involvement in very early systemic sclerosis. Rheumatology (Oxford) 54:72–76

    Article  Google Scholar 

  43. Valentini G, Marcoccia A, Cuomo G, Vettori S, Iudici M, Bondanini F et al (2013) Early systemic sclerosis: marker autoantibodies and videocapillaroscopy patterns are each associated with distinct clinical, functional and cellular activation markers. Arthritis Res Ther 15:R63

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Valentini G, Cuomo G, Abignano G, Petrillo A, Vettori S, Capasso A et al (2011) Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features. Rheumatology (Oxford) 50:317–323

    Article  Google Scholar 

  45. Vettori S, Cuomo G, Iudici M, D’Abrosca V, Giacco V, Barra G et al (2014) Early systemic sclerosis: serum profiling of factors involved in endothelial, T-cell, and fibroblast interplay is marked by elevated interleukin-33 levels. J Clin Immunol 34:663–668

    Article  CAS  PubMed  Google Scholar 

  46. Matucci-Cerinic M, Bellando-Randone S, Lepri G, Bruni C, Guiducci S (2013) Very early versus early disease: the evolving definition of the ‘many faces’ of systemic sclerosis. Ann Rheum Dis 72:319–321

    Article  PubMed  Google Scholar 

Download references

Grants and financial support

None

Conflict of interest

The authors declare they have no conflicts of interest

Author information

Authors and Affiliations

  1. Department of Rheumatology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, 41 110, Larissa, Greece

    Lazaros I. Sakkas, Theodora Simopoulou, Christina Katsiari & Dimitrios Bogdanos

  2. Center for Molecular Medicine, Old Dominion University, Norfolk, VA, USA

    Lazaros I. Sakkas

  3. Division of Transplantation, Immunology and Mucosal Biology, Kings College School of Medicine, University of London, London, UK

    Dimitrios Bogdanos

  4. Department of Rheumatology, Bart’s and the Royal London Hospital, Queen Mary’s School of Medicine and Dentistry, University of London, London, UK

    Ian C. Chikanza

Authors
  1. Lazaros I. Sakkas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Theodora Simopoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christina Katsiari
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dimitrios Bogdanos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ian C. Chikanza
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lazaros I. Sakkas.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sakkas, L.I., Simopoulou, T., Katsiari, C. et al. Early systemic sclerosis—opportunities for treatment. Clin Rheumatol 34, 1327–1331 (2015). https://doi.org/10.1007/s10067-015-2902-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-015-2902-5

Keywords

Search

Navigation